47 filings
8-K
CCCC
C4 Therapeutics Inc
8 Mar 24
Departure of Directors or Certain Officers
4:10pm
8-K
CCCC
C4 Therapeutics Inc
4 Mar 24
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
7:05am
8-K
CCCC
C4 Therapeutics Inc
22 Feb 24
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:15am
8-K
CCCC
C4 Therapeutics Inc
11 Jan 24
Regulation FD Disclosure
7:05am
8-K
CCCC
C4 Therapeutics Inc
9 Jan 24
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
4:06pm
8-K
5tgb46sqkh8hwff0k
12 Dec 23
Regulation FD Disclosure
4:28pm
8-K
6sgl0q
12 Dec 23
Entry into a Material Definitive Agreement
7:15am
8-K
nc494
20 Nov 23
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
7:05am
8-K
gckgxlqpuzj2 ce23bz
1 Nov 23
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
7:18am
8-K
eketn4j
5 Sep 23
C4 Therapeutics Announces Chief Financial Officer Succession
4:02pm
8-K
e4ki z25t
8 Aug 23
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
7:09am
8-K
6brflp9845j72w9qgc
20 Jun 23
C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
7:11am
8-K
lzprk52g8ca z9
30 May 23
Entry into a Material Definitive Agreement
7:30am
8-K
nv0lg 7oalab2akun
4 May 23
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
7:34am
8-K/A
1bdnovh s7pmw86wmk
23 Feb 23
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
4:18pm
8-K
cc2yiuxhsldcmj zs79
23 Feb 23
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
7:42am
8-K
2o4pk55wmulp ol
2 Feb 23
Departure of Directors or Certain Officers
4:03pm
8-K
tbbag49 im
9 Jan 23
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
7:43am
8-K
mhr2 hcbd
3 Nov 22
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
7:21am
8-K/A
1yguz
22 Sep 22
Submission of Matters to a Vote of Security Holders
7:41am